- Home
- DOMO vs TNGX Comparison
DOMO vs TNGX Comparison
Compare DOMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- TNGX
- Stock Information
- Founded
- DOMO 2010
- TNGX 2014
- Country
- DOMO United States
- TNGX United States
- Employees
- DOMO N/A
- TNGX N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMO Technology
- TNGX Health Care
- Exchange
- DOMO Nasdaq
- TNGX Nasdaq
- Market Cap
- DOMO 332.0M
- TNGX 317.4M
- IPO Year
- DOMO 2018
- TNGX N/A
- Fundamental
- Price
- DOMO $8.66
- TNGX $1.77
- Analyst Decision
- DOMO Hold
- TNGX Strong Buy
- Analyst Count
- DOMO 6
- TNGX 7
- Target Price
- DOMO $10.42
- TNGX $12.33
- AVG Volume (30 Days)
- DOMO 341.5K
- TNGX 782.3K
- Earning Date
- DOMO 03-06-2025
- TNGX 05-07-2025
- Dividend Yield
- DOMO N/A
- TNGX N/A
- EPS Growth
- DOMO N/A
- TNGX N/A
- EPS
- DOMO N/A
- TNGX N/A
- Revenue
- DOMO $317,044,000.00
- TNGX $42,069,000.00
- Revenue This Year
- DOMO $0.86
- TNGX N/A
- Revenue Next Year
- DOMO $1.94
- TNGX N/A
- P/E Ratio
- DOMO N/A
- TNGX N/A
- Revenue Growth
- DOMO N/A
- TNGX 15.17
- 52 Week Low
- DOMO $6.11
- TNGX $1.72
- 52 Week High
- DOMO $10.15
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- DOMO 57.77
- TNGX 32.71
- Support Level
- DOMO $8.12
- TNGX $1.80
- Resistance Level
- DOMO $8.65
- TNGX $2.04
- Average True Range (ATR)
- DOMO 0.45
- TNGX 0.21
- MACD
- DOMO 0.09
- TNGX 0.01
- Stochastic Oscillator
- DOMO 94.32
- TNGX 7.46
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.